AC Immune H1 2026: Revenue Jumps to CHF 16.2M, Loss Narrows, and Cash Runway Extends into Q4 2027
ACIU is trading near its 52-week low of $2.03 (9.9% above the low).
Summary
AC Immune's H1 2026 revenue jumped to CHF 16.2M on partner milestones, while the net loss shrank to CHF 12.9M. Cash of CHF 75.4M provides runway into Q4 2027. The filing also formalizes a capital band allowing up to 30% dilution.
Key Events · Earnings and Guidance · ACIU
-
Revenue Surges on Partner Milestones
Contract revenue reached CHF 16.2M in H1 2026, up from CHF 2.3M in H1 2025, driven by a CHF 11M Lilly amendment payment and CHF 5.2M from Takeda collaborations.
-
Net Loss Narrows Sharply
Net loss improved to CHF 12.9M from CHF 40.2M, reflecting lower R&D spend (CHF 22.2M vs CHF 32.7M) after the 2025 restructuring and higher collaboration income.
-
Cash Runway Extended to Q4 2027
Cash and short-term financial assets totaled CHF 75.4M as of June 30, 2026, which management expects to fund operations into Q4 2027, excluding any future milestone payments.
-
Capital Band Formalized — Up to 30% Dilution Possible
Updated Articles of Association reflect the June 2026 shareholder-approved capital band, authorizing the board to increase share capital from 110.1M to as many as 143.1M shares — a potential dilution of approximately 30% if fully utilized.
Analysis · ACIU · Life Sciences
A surge in milestone payments from Takeda and a new Lilly collaboration amendment propelled first-half 2026 revenue to CHF 16.2 million, up sharply from CHF 2.3 million a year ago. The net loss narrowed to CHF 12.9 million from CHF 40.2 million, helped by lower R&D costs following the 2025 restructuring. With cash and short-term investments of CHF 75.4 million, the company expects to fund operations into Q4 2027, eliminating near-term liquidity concerns. The filing also includes updated Articles of Association that formalize the capital band approved in June, giving the board authority to issue up to 143.1 million shares — a potential 30% dilution overhang. Interim clinical updates across the wholly-owned and partnered pipeline set the stage for multiple near-term catalysts, with key data readouts expected in the second half of 2026.
At the time of this filing, ACIU was trading at $2.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $231M. The 52-week trading range was $2.03 to $4.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.